1. Safety of a peanut oral immunotherapy protocol in children with peanut allergy 
Alison M. Hofmann, MD, Amy M. Scurlock, MD, Stacie M. Jones, MD, Kricia P. Palmer, MD, Yuliya Lokhnygina, PhD, Pamela H. Steele, CPNP, Janet Kamilaris, RN, A. Wesley Burks, MD 
Journal of Allergy and Clinical Immunology 
Volume 124, Issue 2, Pages e6 (August 2009)
DOI: /j.jaci
Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2. Fig 1
Estimated risk of specific symptoms during the initial escalation day. Symptoms were recorded during the initial escalation day in 4 categories: upper respiratory tract, skin, abdominal, and chest.
Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci )
Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3. Fig 2
Estimated risk of specific symptoms during the buildup phase. Symptoms were recorded during the buildup phase in 4 categories: upper respiratory tract, skin, abdominal, and chest.
Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci )
Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4. Fig 3
Estimated risk of specific symptoms during the home dosing phase. Symptoms were recorded during the home dosing phase in 4 categories: upper respiratory tract, skin, abdominal, and chest.
Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci )
Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5. Symptom scoring sheet for desensitization and dosage escalations
Symptom scoring sheet for desensitization and dosage escalations. This figure is the description of the symptom classification of mild, moderate, and severe used by trained personnel and parents for recording symptoms during desensitizations, dose escalations, and home dosings.
Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci )
Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions